Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.

[1]  P. Cumming,et al.  Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. , 1986, Life sciences.

[2]  B. Pate,et al.  Routine synthesis of L-[18F]6-fluorodopa with fluorine-18 acetyl hypofluorite. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Grierson,et al.  A practical preparative scale synthesis of d/l‐6‐fluorodopa , 1986 .

[4]  D. Thakker,et al.  Regioselectivity of catechol O-methyltransferase. The effect of pH on the site of O-methylation of fluorinated norepinephrines. , 1986, The Journal of biological chemistry.

[5]  J. Nutt,et al.  The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism , 1985, Annals of neurology.

[6]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[7]  K. Kirk,et al.  The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PETT scanning agents. , 1985, Biochemical and biophysical research communications.

[8]  K. Kirk,et al.  The chemistry and biology of ring‐fluorinated biogenic amines , 1984, Medicinal research reviews.

[9]  C. Nahmias,et al.  Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[11]  S. Fahn,et al.  Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum. , 1982, Biochemical pharmacology.

[12]  S. Fahn,et al.  3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatum , 1982, Annals of neurology.

[13]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[14]  J. Reid,et al.  Parkinsonism treated with 3‐0‐methyldopa , 1973, Clinical pharmacology and therapeutics.

[15]  A. Ericsson.  Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors. , 1971, Journal of the neurological sciences.

[16]  J. W. Miller,et al.  A comparison of certain properties of catechol-O-methyl transferase to those of adrenergic beta receptors. , 1967, The Journal of pharmacology and experimental therapeutics.

[17]  J. Axelrod,et al.  O-Methylation of catechol amines in vivo. , 1958, The Journal of biological chemistry.

[18]  M. Raxworthy,et al.  Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for β-adrenoceptor agents , 1986 .

[19]  C. Weinkove,et al.  Kinetics of enzymatic O-methylation: its value in assays for catecholamines in plasma. , 1984, Clinical chemistry.